Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential.

Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Original Publication: New York, NY : Hindawi Pub. Co.

SELEX Aptamer Technique*; Aptamers, Nucleotide/*therapeutic use ; Carcinoma, Hepatocellular/*pathology ; Liver Neoplasms/*pathology; Binding Sites ; Biotin ; Carcinoma, Hepatocellular/genetics ; Carcinoma, Hepatocellular/therapy ; Cell Line, Tumor ; Humans ; Liver Neoplasms/genetics ; Liver Neoplasms/therapy ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Streptavidin

Relapse and metastasis are two key risk factors of hepatocellular carcinoma (HCC) prognosis; thus, it is emergent to develop an early and accurate detection method for prognostic evaluation of HCC after surgery. In this study, we sought to acquire oligonucleotide DNA aptamers that specifically bind to HCC cells with high metastatic potential. Two HCC cell lines derived from the same genetic background but with different metastatic potential were employed: MHCC97L (low metastatic properties) as subtractive targets and HCCLM9 (high metastatic properties) as screening targets. To mimic a fluid combining environment, initial DNA aptamers library was firstly labelled with magnetic nanoparticles using biotin-streptavidin system and then applied for aptamers selection. Through 10-round selection with subtractive Cell-SELEX, six aptamers, LY-1, LY-13, LY-46, LY-32, LY-27/45, and LY-7/43, display high affinity to HCCLM9 cells and do not bind to MHCC97L cells, as well as other tumor cell lines, including breast cancer, lung cancer, colon adenocarcinoma, gastric cancer, and cervical cancer, suggesting high specificity for HCCLM9 cells. Thus, the aptamers generated here will provide solid basis for identifying new diagnostic targets to detect HCC metastasis and also may provide valuable clues for developing new targeted therapeutics.

Int J Cancer. 2015 Mar 1;136(5):E359-86. (PMID: 25220842)
J Clin Ultrasound. 2008 Jun;36(5):257-66. (PMID: 18088056)
J Cancer Res Clin Oncol. 2003 Jan;129(1):43-51. (PMID: 12618900)
J Infect. 2014 Dec;69(6):569-80. (PMID: 24968239)
Proc Natl Acad Sci U S A. 1987 Oct;84(19):6909-13. (PMID: 3477814)
PLoS One. 2014;9(6):e101015. (PMID: 24968026)
Biomaterials. 2014 Aug;35(25):6998-7007. (PMID: 24857291)
Biochem Biophys Res Commun. 2007 Jun 8;357(3):743-8. (PMID: 17442275)
Mol Clin Oncol. 2013 Jul;1(4):593-598. (PMID: 24649215)
Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):587-95. (PMID: 26810058)
Ann Med. 2013 Nov;45(7):482-7. (PMID: 23962148)
Clin Chem. 2007 Jun;53(6):1153-5. (PMID: 17463173)
J Am Coll Surg. 2010 Oct;211(4):443-9. (PMID: 20822741)
Cancer Res. 2004 Aug 1;64(15):5434-41. (PMID: 15289352)
Acc Chem Res. 2010 Jan 19;43(1):48-57. (PMID: 19751057)
J Hepatol. 2005 Dec;43(6):1007-12. (PMID: 16137783)
ChemMedChem. 2008 Jun;3(6):991-1001. (PMID: 18338423)
Cancer Res. 2004 Oct 15;64(20):7329-35. (PMID: 15492253)
World J Radiol. 2014 Jan 28;6(1):7-14. (PMID: 24578787)
Anal Chim Acta. 2008 Jul 28;621(2):101-8. (PMID: 18573375)
Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11838-43. (PMID: 16873550)
Korean J Intern Med. 2014 Mar;29(2):149-55. (PMID: 24648795)
Bioorg Med Chem Lett. 2013 Mar 15;23(6):1797-802. (PMID: 23403083)
Tumour Biol. 2014 Jan;35(1):9-20. (PMID: 24006223)
Biosens Bioelectron. 2016 Jan 15;75:301-7. (PMID: 26332382)
Exp Cell Res. 2015 Jun 10;334(2):219-27. (PMID: 25773778)
PLoS One. 2013;8(8):e70476. (PMID: 23950940)
BMC Cancer. 2014;14:699. (PMID: 25248985)
Anal Chim Acta. 2015 Jul 23;885:166-73. (PMID: 26231902)
Theranostics. 2015;5(9):985-94. (PMID: 26155314)
World J Gastroenterol. 2013 Jul 14;19(26):4106-18. (PMID: 23864773)
Int J Clin Exp Med. 2015 Jan 15;8(1):1080-6. (PMID: 25785096)
Anal Chem. 2014 May 20;86(10):4956-60. (PMID: 24754473)
PLoS One. 2012;7(4):e36103. (PMID: 22536456)
BMC Cancer. 2006;6:110. (PMID: 16650286)
Int J Mol Sci. 2008 Apr;9(4):668-78. (PMID: 19325777)
Hepatol Res. 2006 Aug;35(4):281-8. (PMID: 16784887)
J Huazhong Univ Sci Technolog Med Sci. 2013 Aug;33(4):520-4. (PMID: 23904371)
PLoS One. 2009;4(11):e7971. (PMID: 19956692)
Ann Surg Oncol. 2011 Jun;18(6):1630-7. (PMID: 21136178)
Lab Chip. 2014 Oct 21;14(20):4017-28. (PMID: 25144781)
J Hematol Oncol. 2014;7:5. (PMID: 24405684)
World J Gastroenterol. 2005 Apr 14;11(14):2061-6. (PMID: 15810069)
Anal Chim Acta. 2014 Jul 21;837:44-51. (PMID: 25000857)
Anal Chem. 2014 Aug 5;86(15):7627-34. (PMID: 25001319)
Hepatology. 2005 Jul;42(1):27-34. (PMID: 15954118)
Biomaterials. 2013 May;34(15):3816-27. (PMID: 23465488)
PLoS One. 2012;7(4):e33434. (PMID: 22558072)
Phys Chem Chem Phys. 2015 Sep 7;17(33):21576-82. (PMID: 26220437)

0 (Aptamers, Nucleotide)
6SO6U10H04 (Biotin)
9013-20-1 (Streptavidin)

Date Created: 20160428 Date Completed: 20161221 Latest Revision: 20181113

20240628

PMC4826907

10.1155/2016/5735869

27119081